Model N announced that it has acquired Kalderos, a technology company that provides a gross-to-net intelligence platform for visibility into 340B drug discount programs.
Model N provides an end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies. The acquisition expands Model N’s revenue management capabilities and extends its 340B offerings for pharmaceutical manufacturers.
The 340B program requires drug manufacturers to sell outpatient drugs at discounted prices to eligible safety-net hospitals and clinics. Model N said 340B is a core and growing component of the gross-to-net value chain.
Manufacturers are managing 340B amid Medicare drug price negotiations, potential future pricing models, and increasing scrutiny of claims-level data requirements. These pressures have increased the need to identify discount discrepancies and reduce revenue leakage.
Kalderos’ Truzo platform provides real-time data visibility across multiple drug discount programs, supporting compliance monitoring, claim validation, and dispute resolution between manufacturers and covered healthcare providers.
Model N said the addition of Kalderos’ 340B data will strengthen its advanced analytics strategy by giving manufacturers more complete information across the revenue lifecycle.
As part of Model N, Kalderos and the Truzo platform will gain access to additional scale, customer relationships, and commercial infrastructure. The combined solution is expected to connect contracting, claims validation, dispute processes, and payment workflows.
Model N recently announced that it manages $1.3 trillion in gross revenue for pharmaceutical and medical technology customers. The company also recently launched Data nSights, an AI-ready integrated data and analytics solution, and expanded agentic workflows across pricing, deal execution, and gross-to-net.
J.P. Morgan Securities acted as exclusive financial advisor to Kalderos. Cooley acted as legal counsel to Kalderos. Kirkland & Ellis acted as legal counsel to Model N.
KEY QUOTES:
“Model N delivers the commercial platform life sciences leaders rely on to expand market access, optimize revenue, and maintain compliance. Through Kalderos, we are providing a more proactive and precise way to manage complex drug pricing programs through a single, fully integrated revenue management solution. This is critical as pricing programs, rebate requirements, and 340B data demands become more complex.”
Bret Connor, CEO of Model N
“Kalderos was built to give manufacturers a transparent, claims-level view of 340B activity, helping them proactively identify non-compliance and reduce revenue leakage. By joining Model N, we’re bringing these capabilities into a revenue management platform already trusted by leading pharmaceutical manufacturers, enabling more informed decisions and better outcomes across the revenue lifecycle.”
Angie Franks, CEO of Kalderos
